Landfar Bio-medicine Co., Ltd (SHE:000504)
China flag China · Delayed Price · Currency is CNY
8.15
-0.12 (-1.45%)
Sep 2, 2026, 3:04 PM CST

Landfar Bio-medicine Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Net Income
33.1828.83-19.85-28.17-12.46-19.13
Depreciation & Amortization
12.037.345.716.346.216.87
Other Amortization
20.9824.0112.189.159.17.26
Loss (Gain) From Sale of Assets
0.03-0-0.16-11.9-0.08-0.03
Asset Writedown & Restructuring Costs
6.562.440.476.920.92.53
Loss (Gain) From Sale of Investments
-5.96-7.71-3.68-0.950.060.31
Provision & Write-off of Bad Debts
8.6312.6712.326.0823.7917.11
Other Operating Activities
8.55-6.467.47-0.13-2.390.38
Change in Accounts Receivable
2.13-173.67-37.389.84135.2147.24
Change in Inventory
-48.192.58-25.41-6.184.824.29
Change in Accounts Payable
-152.8-4.8654.0425.96140.89
Operating Cash Flow
-118.73-115.744.7936.28166.38107.1
Operating Cash Flow Growth
---86.79%-78.20%55.35%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Capital Expenditures
-10.39-5.12-18.26-5.92-16.94-31.96
Sale of Property, Plant & Equipment
0.020.02017.720.330.07
Cash Acquisitions
-63.66-61.232.53---
Divestitures
-10.86-10.86----
Investment in Securities
164.77100-98.190.950.490
Other Investing Activities
2.684.085.59--1.74
Investing Cash Flow
82.5626.89-108.3312.75-16.12-30.15

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Short-Term Debt Issued
----75.1455.86
Long-Term Debt Issued
-269.011828--
Total Debt Issued
279.01269.01182875.1455.86
Short-Term Debt Repaid
---159.79-3.77-145-41.96
Long-Term Debt Repaid
--38.05-39.54-66.97-3.17-3.24
Total Debt Repaid
-52.16-38.05-199.33-70.74-148.17-45.2
Net Debt Issued (Repaid)
226.85230.96-181.33-42.74-73.0310.66
Issuance of Common Stock
---273.7--
Common Dividends Paid
-3.87-2.37-0.91-3.21-2.4-2.12
Other Financing Activities
-17.78-0.31-0.67-1.12-9.720.47
Financing Cash Flow
205.19228.28-182.91226.63-85.159.02

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Foreign Exchange Rate Adjustments
-0-00000
Net Cash Flow
169.02139.43-286.45275.6665.1185.97

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Free Cash Flow
-129.13-120.85-13.4730.36149.4475.14
Free Cash Flow Growth
----79.68%98.89%-
Free Cash Flow Margin
-19.56%-29.06%-10.02%22.19%74.59%47.97%
Free Cash Flow Per Share
-0.40-0.38-0.040.100.480.24
Levered Free Cash Flow
-133.88-210.28-6.1644.79148.9694.32
Unlevered Free Cash Flow
-132.57-208.66-5.2451.71157.03104.3

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Cash Interest Paid
-----0.13
Cash Income Tax Paid
40.8720.4810.7118.259.2416.06
Change in Working Capital
-202.73-176.86-9.6528.94141.2591.79